黄芪注射液辅助PHGF治疗对病毒性肝炎患者肝功能及血清sST2、IL-33的影响  

Effects of Huangqi Injection Assisted PHGF Therapy on Liver Function and Serum sST2 and IL-33 in Patients with Viral Hepatitis

作　　者：黄丽静[1] 邓喜亮 覃金凤 吴海松 潘大烨 梁英源 李锡芳[2] HUANG Li-jing;DENG Xi-liang;QIN Jin-feng;WU Hai-song;PAN Da-ye;LIANG Ying-yuan;LI Xi-fang(Department of Infectious Disease,the First People's Hospital of Qinzhou City,Qinzhou,Guangxi Zhuang Autonomous Region 535000,China;Outpatient Department,the First People's Hospital of Qinzhou City,Qinzhou,Guangxi Zhuang Autonomous Region 535000,China)

机构地区：[1]钦州市第一人民医院感染科,广西壮族自治区钦州535000 [2]钦州市第一人民医院门诊部,广西壮族自治区钦州535000

出　　处：《临床误诊误治》2022年第4期21-25,30,共6页Clinical Misdiagnosis & Mistherapy

基　　金：广西壮族自治区卫生厅自筹经费科研课题(Z.2013750)。

摘　　要：目的探讨黄芪注射液辅助促肝细胞生长素(PHGF)治疗对病毒性肝炎患者肝功能及血清可溶性生长刺激表达基因2蛋白(sST2)、白细胞介素-33(IL-33)、T淋巴细胞免疫功能的影响。方法选取2019年1月—2021年2月收治的病毒性肝炎178例,根据治疗方法不同分为研究组和对照组,每组89例。在常规干预基础上,对照组给予PHGF治疗,研究组给予黄芪注射液辅助PHGF治疗。统计两组临床疗效,比较治疗前后血清丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)、sST2、IL-33水平及T淋巴细胞亚群指标,并观察两组不良反应发生情况。结果研究组临床总有效率高于对照组(P<0.05)。治疗4周后,两组血清AST、ALT、TBIL、sST2及IL-33水平较治疗前降低,且研究组低于对照组(P<0.05);治疗4周后,两组CD3+、CD4+、CD4+/CD8+水平较治疗前增高,且研究组高于对照组(P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论黄芪注射液辅助PHGF治疗病毒性肝炎,可减轻炎症反应,改善患者T淋巴细胞免疫功能和肝功能,且安全可靠,下调sST2及IL-33可能是二者发挥疗效的机制之一。Objective To investigate effects of Huangqi Injection assisted hepatocyte growth factor(PHGF)therapy on liver function and serum soluble growth stimulating expression gene 2 protein(sST2),interleukin-33(IL-33)and T lymphocyte immune function in patients with viral hepatitis.Methods A total of 178 patients with viral hepatitis admitted between January 2019 and February 2021 were selected and divided into research group(n=89)and control group(n=89)according to different therapeutic methods.On the basis of routine intervention,control group was given PHGF therapy,while research group was given Huangqi Injection assisted PHGF therapy.Clinical efficacy was analyzed,and serum levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL),sST2,IL-33 and T lymphocyte subsets were compared before and after treatment,and incidence rates of adverse reactions were observed in two groups.Results The total effective rate in research group was significantly higher than that in control group(P<0.05).After treatment for 4 weeks,serum levels of AST,ALT,TBIL,sST2 and IL-33 were significantly lower than those before treatment in two groups,and the levels in research group were significantly lower than those in control group(P<0.05).After treatment for 4 weeks,levels of CD3+,CD4+and CD4+/CD8+were significantly higher than those before treatment in two groups,and the levels in research group were significantly higher than those in control group(P<0.05).There was no significant difference in the total incidence rate of adverse reactions between two groups(P>0.05).Conclusion Huangqi Injection assisted PHGF therapy in treatment of patients with viral hepatitis may reduce Inflammatory reactions and improve immune function of T lymphocytes and liver function with safe and reliable.Down-regulation of sST2 and IL-33 may be one of the mechanisms for the efficacy.

关 键 词：肝炎 病毒性 黄芪注射液 促肝细胞生长素 可溶性生长刺激表达基因2蛋白 白细胞介素-33 

分 类 号：R512.6[医药卫生—内科学]